The Safety and Efficacy of Fecal Microbiota Transplant (FMT) for Steroid-refractory Graft-versus-host Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

46 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-04-27

Study Completion Date

2024-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This clinical study evaluates the safety and efficacy of fecal microbiota transplantation (FMT) in patients with steroid-refractory graft-versus-host disease (GVHD).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

FMT in Gut aGVHD Treated

NCT03148743

Acute-graft-versus-host Disease

RECRUITING

A Real-World Study of Fecal Transplants for Cancer Therapy Side Effects

NCT07319364

Fecal Microbiota Transplantation (FMT) Gastrointestinal Neoplasms Antineoplastic Agents +1 more

RECRUITING PHASE1

Correlation Between Gut Microbiota and Clinical Response to CAR-T Treatment for Hematological Malignancies

NCT06041815

Hematological Malignancies Chimeric Antigen Receptor T-cell Therapy

UNKNOWN

Fecal Microbiota Transplant (FMT) Capsule for Improving the Efficacy of Anti- PD-1

NCT04130763

Gastrointestinal System Cancer

COMPLETED PHASE1

Fecal Microbiota Transplantation for Radiation Enteritis

NCT03516461

Radiation Enteritis

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

GVHD

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with refractory graft-versus-host disease

FMT for patients with refractory GVHD

Group Type EXPERIMENTAL

Fecal Microbiota Transplant (FMT)

Intervention Type OTHER

FMT in patients with refractory GVHD

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fecal Microbiota Transplant (FMT)

FMT in patients with refractory GVHD

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Able and willing to sign the informed consent form and complete follow-up;
2. Aged 18-65 years, regardless of gender;
3. Patients with refractory GVHD.

Exclusion Criteria

1. life-threatening or associated with severe non-GvHD complications;
2. Persistent malignant conditions;
3. Patients who have undergone second or multiple hematopoietic stem cell transplants;
4. History of severe allergic reactions;
5. Any condition that the investigator considers unsuitable for inclusion (such as any history, treatment history, or abnormal test data that may confound the study results, interfere with full participation in the study, or harm the patient's interests);

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No